cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...

Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...

The FDA approved the enzyme replacement therapy Adzynma for the prophylactic or on-demand treatment of adults and pediatric patients with congenital thrombotic thrombocytopenic purpura, a rare blood ...

Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

For the past two years, the research lab of X. Long Zheng, M.D., Ph.D., Division Director, Laboratory Medicine, UAB Department of Pathology, has hosted an annual Thrombotic Thrombocytopenic Purpura ...

Including biomarkers for non-ADAMTS13 in routine clinical testing could benefit diagnosis and follow-up in patients with immune-mediated thrombotic thrombocytopenic purpura (TTP). Patients with immune ...

Takeda Pharmaceutical Co Ltd (NYSE:TAK) stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda’s Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency ...

For reference, ADAMTS13 is a key regulator of blood clotting, preventing excessive clot formation in normal circulation. Its primary function is to cleave vWF, a large protein that helps platelets ...

Takeda announced it is launching Adzynma (ADAMTS13, recombinant-krhn) following the recent approval by the Food and Drug Administration. The drug is intended for the prophylactic and on-demand ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover ...